- Home
- / United Therapeutics
United Therapeutics
Stock Price
$352.8
2024-10-29
Market Capitalization
$15.7 B
2024-10-29
Revenue
$2.9 B
FY, 2024
United Therapeutics Summary
Company Summary
- Overview
- United Therapeutics Corporation is a company that develops products for chronic and life-threatening disease treatment. It offers Remodulin injections, Tyvaso inhalation powders, Orenitram oral medicine, Adcirca phosphodiesterase 5 inhibitors, etc. The company provides its products to patients with pulmonary arterial hypertension, neuroblastoma, and end-stage lung disease.
- Type
- Public
- Status
- Active
- Founded
- 1996
- HQ
- Silver Spring, MD, US | view all locations
- Website
- https://www.unither.com/
- Cybersecurity rating
- ESG rating
Table of Contents
LocationsView all
6 locations detected
Silver Spring, MD HQ
United States
1000 Spring St
Durham, NC
United States
55 TW Alexander Dr
Jacksonville, FL
United States
Manchester, NH
United States
Melbourne, FL
United States
Washington, DC
United States
United Therapeutics Financials
Summary Financials
- Revenue (FY, 2024)
- $2.9B
- Gross profit (FY, 2024)
- $2.6B
- Net income (FY, 2024)
- $1.2B
- Cash (FY, 2024)
- $1.7B
- EBIT (FY, 2024)
- $1.4B
- Enterprise value
- $14.3B
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2025